Litcius/Paper detail

Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)

Guixian Zhu, Dian Gao, Zhaozhao Shao, Li Chen, Wenjie Ding, Qiongfang Yu

2020Molecular Medicine Reports59 citationsDOIOpen Access PDF

Abstract

Colorectal cancer (CRC) is the third most common malignant tumor in humans. Chemotherapy is used for the treatment of CRC. However, the effect of chemotherapy remains unsatisfactory due to drug resistance. Growing evidence has shown that the presence of highly metastatic tumor stem cells, regulation of non‑coding RNAs and the tumor microenvironment contributes to drug resistance mechanisms in CRC. Wnt/β‑catenin signaling mediates the chemoresistance of CRC in these three aspects. Therefore, the present study analyzed the abundant evidence of the contribution of Wnt/β‑catenin signaling to the development of drug resistance in CRC and discussed its possible role in improving the chemosensitivity of CRC, which may provide guidelines for its clinical treatment.

Topics & Concepts

Wnt signaling pathwayColorectal cancerOncogeneDrug resistanceCancer researchMolecular medicineChemotherapyCancerCateninBiologyCell cycleDrugOncologyMedicineInternal medicineSignal transductionPharmacologyGeneticsWnt/β-catenin signaling in development and cancerCancer Cells and MetastasisCancer Immunotherapy and Biomarkers
Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review) | Litcius